GlassScriptPhysician profile
Elizabeth Ann Bourret
NPI 1568727519
$3,438.42
in general payments reported to CMS, 2019-2025
33 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $359 · 2020: $330 · 2021: $529 · 2022: $512 · 2023: $581 · 2024: $672 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,708.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,708.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $582.81 | 2019-2025 | Apligraf, Affinity, Cygnus Dual |
| Smith+Nephew, INC. | $445.40 | 2019-2024 | Regranex, Collagenase Santyl, Stravix |
| Paratek Pharmaceuticals, INC. | $366.22 | 2020-2024 | Nuzyra |
| Melinta Therapeutics, LLC | $340.29 | 2019-2024 | Kimyrsa, Orbactiv |
| Hydrofera LLC | $201.82 | 2023-2024 | Hydrofera Blue, Hydrofera Blue Ready - Border |
| Stryker Corporation | $192.37 | 2019-2024 | Easyfuse |
| Wright Medical Technology, INC. | $163.43 | 2019-2020 | |
| Averitas Pharma INC. | $143.37 | 2023-2025 | Qutenza |
| Convatec INC. | $136.01 | 2023-2025 | |
| Checkpoint Surgical, INC | $115.35 | 2021-2025 | Checkpoint Stimulators |
| Integra Lifesciences Corporation | $65.52 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $58.50 | 2021-2025 | Exparel |
| Horizon Therapeutics Plc | $55.86 | 2019-2023 | Krystexxa |
| Bioventus LLC | $50.48 | 2020-2025 | Exogen Ultrasound Bone Healing System |
| Kci USA, INC. | $47.25 | 2019-2023 | Promogran, V.A.C. Dermatac, Activ.A.C. |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Trice Medical, INC. | $45.66 | 2021 | |
| Triad Life Sciences INC. | $41.08 | 2022 | |
| Next Science LLC | $37.28 | 2023 | Surgx, Xperience, Blastx |
| Nabriva Therapeutics, Plc | $35.77 | 2021-2022 | |
| Abbott Laboratories | $34.50 | 2021-2023 | Proclaim |
| Medtronic, INC. | $28.53 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Misonix INC | $28.28 | 2020 | |
| Heron Therapeutics, INC. | $27.80 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $26.48 | 2025 | |
| Ani Pharmaceuticals, INC. | $25.67 | 2025 | Purified Cortrophin Gel |
| Kerecis Limited | $25.10 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Osiris Therapeutics INC. | $21.21 | 2019 | |
| Sebela Pharmaceuticals INC. | $20.18 | 2023 | Naftin, Pramosone |
| Grt US Holding, INC. | $18.83 | 2022 | |
| Access Pro Medical, LLC | $16.08 | 2022 | |
| Aroa Biosurgery Incorporated | $14.57 | 2019 | |
| Dynasplint Systems INC. | $13.72 | 2023 | Dynasplint |
| Arteriocyte Medical Systems, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Bourret listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.